Novartis Approvals Dominate Rx-To-OTC Switches In 1999
This article was originally published in The Tan Sheet
Novartis Consumer Health cornered the Rx-to-OTC switch landscape in 1999, receiving approval for and bringing to market former Rx drugs Lamisil AT and Habitrol.
You may also be interested in...
J&J/Merck is requesting several exemptions from provisions of the OTC labeling final rule for sample pouches of the firm's Pepcid AC Gelcaps.
Novartis plans to spend $20 mil. on TV and print advertising in 1999 to launch Lamisil AT, the firm's new OTC athlete's foot medication. An Rx-to-OTC switch of the 1% terbinafine cream was approved by FDA March 9 ("The Tan Sheet" March 15, p. 11).
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC